Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cyclopentolate→

Cyclopentolate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
512-15-2
Molecular formula
C17H25NO3
Molecular weight
291.4 g/mol
Drug class
Antimuscarinic ophthalmic agentmydriatic and cycloplegic
Mechanism of action
Blocks muscarinic cholinergic responses in the iris sphincter and ciliary muscle, producing pupillary dilation (mydriasis) and temporary paralysis of accommodation (cycloplegia).
Indications / reported uses
  • Pupil dilation and cycloplegia before ophthalmic examination and refraction

Sources: US DailyMed — Cyclopentolate hydrochloride ophthalmic solution · US National Library of Medicine MedlinePlus · Australian Commission on Safety and Quality in Health Care

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antimuscarinic ophthalmic agent; mydriatic and cycloplegic

Mechanism of action

Blocks muscarinic cholinergic responses in the iris sphincter and ciliary muscle, producing pupillary dilation (mydriasis) and temporary paralysis of accommodation (cycloplegia).

General use cases

  • Pupil dilation and cycloplegia before ophthalmic examination and refraction

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cyclopentolate Environmental Risk Assessment (ERA) (the Cyclopentolate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.